54191-12-7

Basic information

• Product Name: N-(4-nitrophenyl)butanamide
• Synonyms: N-(4-nitrophenyl)butanamide
• CAS NO: 54191-12-7
• Molecular Formula: C₁₀H₁₂N₂O₃
• Molecular Weight: 208.21388
• Mol File: 54191-12-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 417.3°Cat760mmHg
• Flash Point: 206.1°C
• Appearance: /
• Density: 1.244g/cm³
• Vapor Pressure: 3.59E-07mmHg at 25°C
• Refractive Index: 1.588
• CAS DataBase Reference: N-(4-nitrophenyl)butanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-nitrophenyl)butanamide(54191-12-7)
• EPA Substance Registry System: N-(4-nitrophenyl)butanamide(54191-12-7)

Safety Data

• Hazardous Substances Data: 54191-12-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H12N2O3/c1-2-3-10(13)11-8-4-6-9(7-5-8)12(14)15/h4-7H,2-3H2,1H3,(H,11,13)

Upstream product

• 100-01-6 4-nitro-aniline 
• 133-13-1 ethyl diethyl malonate 
• 636-98-6 p-nitrobenzene iodide 
• 541-35-5 butanamide 
• 106-31-0 butanoic acid anhydride 
• 141-75-3 butyryl chloride 

Downstream Products

• 100-01-6 4-nitro-aniline 
• 109817-62-1 1-(4'-aminophenyl)-5-propyl-1H-tetrazole 
• 1596358-22-3 1-(4'-nitrophenyl)-5-propyl-1H-tetrazole 
• 58259-34-0 N-butyl-4-nitroaniline 
• 116884-02-7 butyric acid-(4-amino-anilide) 

Relevant articles and documents

Phenanthridin-6-one derivatives as the first class of non-steroidal pharmacological chaperones for Niemann-Pick disease type C1 protein

Niemann-Pick disease type C is a fatal, progressive neurodegenerative disease mostly caused by mutations in Nieamnn-Pick type C1 (NPC1), a late endosomal membrane protein that is essential for intracellular cholesterol transport. The most prevalent mutation, I1061T (Ile to Thr), interferes with the protein folding process. Consequently, mutated but intrinsically functional NPC1 proteins are prematurely degraded via proteasome, leading to loss of NPC1 function. Previously, we reported sterol derivatives as pharmacological chaperones for NPC1, and showed that these derivatives can normalize folding-defective phenotypes of I1061T NPC1 mutant by directly binding to, and stabilizing, the protein. Here, we report a series of compounds containing a phenanthridin-6-one scaffold as the first class of non-steroidal pharmacological chaperones for NPC1. We also examined their structure-activity relationships.

Malonic ester amide synthesis: An efficient methodology for synthesis of amides

A general methodology malonic ester amide synthesis has been demonstrated, which uses α-substituted/unsubstituted diethyl malonates for the decarboxylative acylation of various aromatic/heteroaromatic primary/secondary amines to form one-carbon homologated amides, thus providing easy access to amides with odd/even chain lengths and an array of substituents on the alkyl/aryl part while avoiding use of acyl chlorides or peptide coupling reagents. Copyright

Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds

The present invention relates to a novel retinoid derivative compound represented by the formula I: wherein X, R1, R2 and R3 are as defined herein or pharmaceutically acceptalbe salts thereof. Also, the present invention relates to processes for producing the compound of the formula I and to an anti-cancer composition comprising the compound of the formula I. The compound of the formula I according to the present invention exerts high anti-cancer effects while not causing undesirable side effects.